Additional studies revealed that patients with low abundance of Bacteroidetes and elevated Faecalibacterium prausnitzii and other related Firmicutes harbored an elevated risk of colitis in anti-CTLA-4 therapy (176, 178). The gene discussed is CTLA4; the disease is colitis.